Key result
Recombinant hirudin successfully served as an alternative anticoagulant to heparin for cardiopulmonary bypass during CABG in a patient with heparin-induced thrombocytopenia.
Why the study?
Can recombinant hirudin be safely used as an anticoagulant for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia undergoing CABG?
Can recombinant hirudin be safely used as an anticoagulant for cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia undergoing CABG?
Recombinant hirudin can be successfully used as an alternative anticoagulant for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia undergoing CABG.
May support recombinant hirudin for CPB in HIT during CABG; single case leaves open need for prospective validation.
We present a patient with coronary heart disease and a heparin- induced thrombocytopenia , who was successfully treated by coronary ar- tery bypass grafting (CABG) using recombinant hirudin as an anticoagu- lant for cardiopulmonary bypass (CPB) instead of heparin. (Eur J Car- dio-thorac Surg (1996) 10: 386-388)
No takes yet. Share an insight, caveat, or question.
Rieß et al. (1996) studied this question. Recombinant hirudin successfully served as an alternative anticoagulant to heparin for cardiopulmonary bypass during CABG in a patient with heparin-induced thrombocytopenia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: